Krebiozen

Last updated

Krebiozen (aka Carcalon, creatine, substance X, or drug X) is a disproven cancer treatment that is made available as an alternative cancer treatment. While the substance has been marketed as a cure for cancer, originally sold for thousands of dollars per dose in the 1950s and early '60s, Krebiozen is not known to possess any therapeutic value. Attempts to analyze its composition have shown that Krebiozen consists only of the amino acid creatine dissolved in mineral oil, and some samples sold as Krebiozen consist solely of mineral oil with no other discernible ingredients. [1] [2] [3]

Contents

The American Cancer Society states: "Available scientific evidence does not support claims that Krebiozen is effective in treating cancer or any other disease." According to the U.S. Food and Drug Administration (FDA), Krebiozen has been linked to several dangerous side effects. [4]

History and evaluation

Krebiozen was initially promoted by Stevan Durovic, a Yugoslavian physician who claimed that the substance came from horse serum inoculated with Actinomyces bovis . [1] Durovic claimed that Krebiozen had been useful in the treatment of cancer, mainly in cats and dogs. His claims were backed by Andrew Conway Ivy, a prominent physiologist, and by several politicians including Senator Paul Douglas (D-IL). [1] Ivy became convinced that Krebiozen possessed anti-cancer properties, [5] administered the substance to himself and colleagues, then to a dog, and eventually started testing Krebiozen on patients. [2]

Ivy called a press conference in 1951 at which he announced to an audience of journalists, politicians, doctors and potential investors that Krebiozen was a success. At the press conference, Ivy claimed that of 22 treated patients, 14 were alive and none had died of cancer. However, in reality 10 of the treated patients had died—all of cancer—at the time of the press conference. [2] Shortly afterward, the Krebiozen Research Foundation was established by the Durovic brothers, with Ivy as president.

Intrigued by Ivy's announcement, 10 hospitals and cancer research centers followed up on the trial and attempted to reproduce Ivy's claimed results. None of these independent researchers observed any effect of Krebiozen on cancer. A compilation of these institutions' negative data was reported in the Journal of the American Medical Association in 1951. [6] Krebiozen's backers responded by alleging a conspiracy against the drug. [2] In 1959, Ivy began producing his own version of the drug under the name "Carcalon". [7]

On October 28, 1964, the Durovics, Ivy and the Krebiozen Research Foundation were indicted for introducing mislabeled drugs into interstate commerce in violation of the Food, Drug and Cosmetic Act. After a 9-month trial, the case ended with a hung jury and they were acquitted. [2] [8] Soon afterwards, Durovic was indicted for tax evasion and fled the United States. [7]

Composition

In order to evaluate Durovic's and Ivy's claims, the National Cancer Institute (NCI) requested samples of Krebiozen. These were provided on two occasions to the NCI and one occasion to the U.S. Food and Drug Administration (FDA). Durovic proposed to charge the NCI $170,000 per gram of Krebiozen, although ultimately the samples were provided free of charge. However, the FDA spectrophotometry team, led by Alma Levant Hayden, proved the samples consisted only of creatine monohydrate, a simple amino acid, sometimes dissolved in mineral oil. [1] [2] [5] [7] [9] When the FDA went back to test previously acquired samples of Krebiozen, they found that many lacked even creatine, and consisted solely of mineral oil with no discernible active ingredients. [2]

See also

Related Research Articles

<span class="mw-page-title-main">Dietary supplement</span> Product providing additional nutrients

A dietary supplement is a manufactured product intended to supplement a person's diet by taking a pill, capsule, tablet, powder, or liquid. A supplement can provide nutrients either extracted from food sources, or that are synthetic. The classes of nutrient compounds in supplements include vitamins, minerals, fiber, fatty acids, and amino acids. Dietary supplements can also contain substances that have not been confirmed as being essential to life, and so are not nutrients per se, but are marketed as having a beneficial biological effect, such as plant pigments or polyphenols. Animals can also be a source of supplement ingredients, such as collagen from chickens or fish for example. These are also sold individually and in combination, and may be combined with nutrient ingredients. The European Commission has also established harmonized rules to help insure that food supplements are safe and appropriately labeled.

<span class="mw-page-title-main">Nootropic</span> Compound intended to improve cognitive function

Nootropics, colloquially brain supplements, smart drugs and cognitive enhancers, are natural, semisynthetic or synthetic compounds which purportedly improve cognitive functions, such as executive functions, attention or memory.

Essiac is a herbal tea promoted as an alternative treatment for cancer and other illnesses. There is no evidence it is beneficial to health. In a number of studies Essiac either showed no action against cancer cells, or actually increased the rate of cancer growth.

The Burzynski Clinic is a clinic selling an unproven cancer treatment, which has been characterized as harmful quackery. It was founded in 1976 and is located in Houston, Texas, in the United States. It offers a form of chemotherapy originally called "antineoplaston therapy" devised by the clinic's founder Stanislaw Burzynski in the 1970s. Antineoplaston is Burzynski's term for a group of urine-derived peptides, peptide derivatives, and mixtures. There is no accepted scientific evidence of benefit from antineoplaston combinations for various diseases, and the Clinic's claimed successes have not been replicated by independent researchers. The therapy has been rebranded in various ways over the years to mirror fashions in medicine, for example as a kind of "immunotherapy". The therapy is administered through the ruse of running a large numbers of clinical trials, which long-time Burzynski lawyer Richard Jaffe has described as "a joke".

<span class="mw-page-title-main">Cannabidiol</span> Phytocannabinoid discovered in 1940

Cannabidiol (CBD) is a phytocannabinoid, one of 113 identified cannabinoids in cannabis plants, along with tetrahydrocannabinol (THC), and accounts for up to 40% of the plant's extract. Medically, it is an anticonvulsant used to treat multiple forms of epilepsy. It was discovered in 1940 and, as of 2022, clinical research on CBD included studies related to the treatment of anxiety, addiction, psychosis, movement disorders, and pain, but there is insufficient high-quality evidence that CBD is effective for these conditions. CBD is sold as an herbal dietary supplement and promoted with yet unproven claims of particular therapeutic effects.

<span class="mw-page-title-main">Max Gerson</span> German-American physician (1881–1959)

Max Gerson was a German-born American physician who developed the Gerson therapy, a dietary-based alternative cancer treatment that he claimed could cure cancer and most chronic, degenerative diseases. Gerson therapy involves a plant-based diet with coffee enemas, ozone enemas, dietary supplements and raw calf liver extract, the latter was discontinued in the 1980s after patients were hospitalized for bacterial infections.

Off-label use is the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration. Both prescription drugs and over-the-counter drugs (OTCs) can be used in off-label ways, although most studies of off-label use focus on prescription drugs.

Bodybuilding supplements are dietary supplements commonly used by those involved in bodybuilding, weightlifting, mixed martial arts, and athletics for the purpose of facilitating an increase in lean body mass. Bodybuilding supplements may contain ingredients that are advertised to increase a person's muscle, body weight, athletic performance, and decrease a person's percent body fat for desired muscle definition. Among the most widely used are high protein drinks, pre-workout blends, branched-chain amino acids (BCAA), glutamine, arginine, essential fatty acids, creatine, HMB, whey protein, ZMA, and weight loss products. Supplements are sold either as single ingredient preparations or in the form of "stacks" – proprietary blends of various supplements marketed as offering synergistic advantages.

714-X, also referred to as 714X or trimethylbicyclonitramineoheptane chloride, is a mixture of substances manufactured by CERBE Distribution Inc and sold as an alternative medical treatment which is claimed to cure cancer, multiple sclerosis, fibromyalgia and other diseases. There is no scientific evidence that 714-X is effective in treating any kind of cancer, and its marketing is considered health fraud in the US.

Hoxsey Therapy or Hoxsey Method is an alternative medical treatment promoted as a cure for cancer. The treatment consists of a caustic herbal paste for external cancers or a herbal mixture for "internal" cancers, combined with laxatives, douches, vitamin supplements, and dietary changes. Reviews by major medical bodies, including the U.S. Food and Drug Administration (FDA), the National Cancer Institute, the American Cancer Society, M. D. Anderson Cancer Center, and Memorial Sloan-Kettering Cancer Center, have found no evidence that Hoxsey Therapy is an effective treatment for cancer. The sale or marketing of the Hoxsey Method was banned in the United States by the FDA on September 21, 1960 as a "worthless and discredited" remedy and a form of quackery.

Poly-MVA is a dietary supplement created by Merrill Garnett (1931–), a former dentist turned biochemist. Poly-MVA is an unproven alternative cancer treatment.

Reslizumab, sold under the brand names Cinqair and Cinqaero, is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.

A protein kinase inhibitor (PKI) is a type of enzyme inhibitor that blocks the action of one or more protein kinases. Protein kinases are enzymes that phosphorylate (add a phosphate, or PO4, group) to a protein and can modulate its function.

Cancell, also called Protocel, Sheridan's Formula, Jim's Juice, Crocinic Acid, JS–114, JS–101, 126–F, and Entelev, is a formula that has been promoted as a treatment for a wide range of diseases, including cancer. Cancell is available in tablet and liquid form. Originally called Entelev, the formula was developed by biochemist James V. Sheridan. Sheridan sought to target the primarily anaerobic cell metabolism of cancer cells, claiming to lower cell potential leading to the destruction of cancer cells. The Cancell formula was tested by the National Cancer Institute and found to be ineffective against cancer, though Cancell continues to be marketed as a dietary supplement in the US.

<span class="mw-page-title-main">Andrew Conway Ivy</span> American physician

Andrew Conway Ivy was an American physician. He was appointed by the American Medical Association as its representative at the 1946 Nuremberg Medical Trial for Nazi doctors, but later fell into disrepute for advocating the fraudulent drug Krebiozen.

A glossary of terms used in clinical research.

<span class="mw-page-title-main">Trastuzumab emtansine</span> Pharmaceutical drug

Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. The conjugate is abbreviated T-DM1.

<span class="mw-page-title-main">Tucatinib</span> Chemical compound

Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics.

<span class="mw-page-title-main">Alma Levant Hayden</span> American chemist

Alma Levant Hayden was an American chemist, and one of the first African-American women to gain a scientist position at a science agency in Washington, D.C. She joined the National Institutes of Health (NIH) in the 1950s. Hayden graduated from Howard University with a master's degree in chemistry, and became an expert in spectrophotometry, the measurement of how substances absorb light. She published work on infrared and other techniques for analyzing chemicals in a range of journals. Hayden was appointed Chief of the Spectrophotometer Research Branch in the Division of Pharmaceutical Chemistry at the U.S. Food and Drug Administration (FDA) in 1963, and may have been the first African-American scientist at the FDA. Hayden came to national attention in 1963 when she led the team that exposed the common substance in Krebiozen, a long-controversial alternative and expensive drug promoted as anti-cancer.

References

  1. 1 2 3 4 "Krebiozen Analyzed". Time . 1963-09-13. Archived from the original on December 22, 2008. Retrieved 2014-07-29.
  2. 1 2 3 4 5 6 7 Holland, James (1966-10-07). "The Krebiozen Story". Quackwatch . Retrieved 2008-10-09.
  3. ↑ Ehrlich, Matthew (2024-08-20). ""Deceit, delusion, and a classic medical fraud": An excerpt from a new book about a cancer treatment hoax". Retraction Watch. Archived from the original on 2024-08-21. Retrieved 2024-08-21.
  4. ↑ "Krebiozen". American Cancer Society. 1 November 2008. Retrieved 1 June 2017.
  5. 1 2 "Krebiozen". British Columbia Cancer Agency. February 2000. Archived from the original on 2008-04-16. Retrieved 2008-10-09.
  6. ↑ "STATUS report on "krebiozen"". J Am Med Assoc. 147 (9): 864–73. October 1951. PMID   14873580.
  7. 1 2 3 "Krebiozen". American Cancer Society. 20 July 2007. Archived from the original on 29 October 2008. Retrieved 1 June 2017.
  8. ↑ "The Krebiozen Verdict". Time . 1966-11-02. Archived from the original on February 22, 2008. Retrieved 2014-07-29.
  9. ↑ Loory, Stuart H. (8 September 1963). "Student found clue to Krebiozen identity shortly after starting work on 20,000 spectrographs". St. Louis Post-Dispatch. p. 24. Retrieved 7 May 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.